CANNABIS EXPLAINER
Cannabis Legalization by State
As of 2025, 24 states have legalized recreational cannabis for adults 21+.
CANNABIS EXPLAINER
As of 2025, 24 states have legalized recreational cannabis for adults 21+.
| Category | States Count | Examples |
|---|---|---|
| Recreational Legal | 24 states + DC | California, Colorado, Illinois, NY |
| Medical Only | 14 states | Florida, Texas, Virginia, PA |
| Decriminalized | 10 states | North Carolina, Nebraska |
| Fully Illegal | 2 states | Idaho, Kansas |
As of 2025, 24 states plus Washington D.C. have legalized recreational cannabis for adults 21 and older. These include California, Colorado, Washington, Oregon, Nevada, Michigan, Illinois, New York, New Jersey, and others. Each state operates its own regulatory system with different possession limits, retail regulations, and tax structures. Prices and product availability vary significantly by state.
Fourteen states permit cannabis use only for qualifying medical conditions with a physician's recommendation and a state-issued medical cannabis card. Medical programs typically allow higher possession limits than recreational programs and often feature lower tax rates. Qualifying conditions vary by state but typically include cancer, epilepsy, multiple sclerosis, chronic pain, PTSD, and AIDS/HIV.
Some states have removed criminal penalties for small amounts of cannabis possession (typically up to 1 ounce) without fully legalizing it. Possession in these states may result in a civil fine rather than arrest and prosecution. Cannabis remains illegal in these states — there are no legal dispensaries — but enforcement is reduced for minor possession.
Cannabis remains a Schedule I controlled substance under federal law regardless of state legalization. This creates legal complexities: cannabis cannot cross state lines even between two legal states, federally licensed banks are reluctant to serve cannabis businesses, and federal employees and contractors are generally prohibited from cannabis use. Federal rescheduling discussions have been ongoing, with DEA review of Schedule III classification active in 2024-2025.